Special Issue

Diagnostics, Antiviral Therapy and Vaccination against Orthopoxvirus Infections

Message from the Guest Editors

In the decades since the eradication of smallpox, the human population has almost completely lost herd immunity, not only against smallpox but also against other zoonotic orthopoxviruses. To date, this has led to the fact that outbreaks of human infections caused by monkeypox, cowpox, buffalopox, or vaccinia viruses are increasingly being recorded on different continents, and the risk of widespread epidemics of orthopoxvirus infections is increasing. Therefore, the development of new diagnostic methods, creation of antivirals, and modern vaccines against orthopoxviruses are of particular importance. This Special Issue will review the latest research findings on the development of express diagnostic methods, the search for effective antivirals, and the creation of modern safe vaccines against orthopoxvirus infections.

Guest Editors

Prof. Dr. Sergei N. Shchelkunov

State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo, Novosibirsk, Russia

Dr. Larisa N. Shishkina

State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, Koltsovo, Novosibirsk, Russia

Deadline for manuscript submissions

closed (27 September 2023)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/119486

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).